TIDMPSY
RNS Number : 2230O
Psych Capital PLC
09 June 2022
Psych Capital Plc
("Psych Capital" or the "Company")
Admission to trading on AQSE
Psych Capital Plc, the psychedelic healthcare incubation and
investment company, that operates the leading industry data,
insights, and networking platform, PSYCH, with over 20,000+
subscribers and over 3,000 delegates to previous events, is pleased
to announce that admission of its shares to trading on the Aquis
Stock Exchange Growth Market ("AQSE Growth Market") will commence
at 8.00a.m. today under the TIDM "PSY" and the ISIN number
GB00BL6CJQ54.
The Company's Admission Document is available at the Company's
website: https://psych.capital
Key Highlights
-- The Company currently has exposure to key segments of the
medical psychedelic sector through strategic acquisitions and
investments, including:
-- Clinical research in connection with the development of
psychedelic medicines used to treat addiction;
-- Data collection in relation to developments in the
psychedelic sector (including, the legal framework, commerce and
science); and
-- Media and communications platform for the medical psychedelic industry
-- The Company intends to identify, fund and support the
building of future companies across three core pillars: therapeutic
treatments, drug development, and data/artificial intelligence
-- The Company will leverage its portfolio of brands, and
network of experts, to identify early-stage opportunities in the
medical psychedelic industry
-- The Psych Platform is a global B2B resource for networking,
intelligence, and insights, servicing the industry through
publications, newsletters and engaging events
-- PSYCH Symposium events generate strong revenue through sponsorship and ticket sales.
Compelling Investment Proposition
Psych Capital is a publicly listed incubation and investment
firm that deploys early stage capital whilst building or supporting
new companies in Europe's psychedelic science and healthcare
industry.
PSYCH is a data and intelligence platform for the psychedelic
science and healthcare industry. It has quickly become the
industry's leading resource - powered by trustworthy data,
independent analysis and engaging events that attract a highly
influential audience of policy makers, scientists and
investors.
Market Opportunity
The nascent psychedelics' space is quickly being harnessed by a
growing base of institutional investors seeking to establish and
scale businesses in a landscape showing scientific and commercial
promise.
-- Psych's offering aims to capitalise on the following market dynamics:
-- Numerous companies are currently creating training plans for
psychedelic therapists, including the MIND Foundation and COMPASS
Pathway;
-- The United Nations (UN) Convention on Psychotropic Substances
framework for the international control of psychotropic substances
lists: Psilocybin, MDMA, DMT and LSD as Schedule I substances, the
category indicating the least harm with medical application;
-- Ketamine is on the WHO list of essential medicines;
-- Psilocybin therapy is expected to be a key driver in societal
education and a contributor to wider reforms across America;
-- MDMA-assisted therapy can take a strong market share from 2024;
-- Capital invested in psychedelic companies is over US$2 billion; and
-- The current value of medical businesses surpasses US$10
billion. For example, ATAI Life Sciences' initial public offering
(IPO) last year made it the most valuable publicly-traded business
in the sector, currently valued at US$595 million.
Placing
The Company has raised gross proceeds of GBP810k from the issue
and allotment of 16,200,000 Placing Shares.
The Company intends to apply the net proceeds raised from the
fundraising activities to support its general working capital
requirements and to develop its existing business, whilst certain
funds may be applied to enable the Company to make further
acquisitions.
Total voting rights
Following Admission, the total number of Ordinary Shares in
issue will be 290,033,335 each with equal voting rights. The
Company does not hold any rights in treasury. The total voting
rights figure can be used by Shareholders as the denominator for
the calculations by which they will determine whether they are
required to notify their interest in, or a change of their interest
in, the Company under the Disclosure Guidance and Transparency
Rules of the Financial Conduct Authority.
William Potts, Chief Investment Officer and Co-Founder of Psych
Capital, commented: "We're the first pure play Psychedelic company
to list on a UK stock market at an inflection point for the
industry as global interest moves towards the UK due to the leading
science and companies here. We believe our IPO is a milestone for
the whole psychedelic industry in the UK.
"With an escalating global mental health crisis, there's a
significant opportunity for innovation to cater to unmet needs and
improve patient outcomes worldwide. Encouraged by breakthrough
trials and science of psychedelic-assisted therapy, our mission is
to support a new wave of innovators who are well positioned to
challenge the status-quo and revolutionise how society deals with
mental health conditions."
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please contact:
Psych Capital Plc
Stephen Murphy, Executive
Director
William Potts, Chief Investment info@PSYCH.capital or via Walbrook
Officer PR Ltd psych@walbrookpr.com
AQSE Growth Market Corporate
Adviser
Peterhouse Capital Limited Tel: +44 (0) 207 469 0930
Guy Miller / Mark Anwyl
Walbrook PR Ltd (Media & Tel: +44 (0)20 7933 8780 or psych@walbrookpr.com
Investor Relations)
Nick Rome / Tom Cooper Mob: +44 (0) 7748 325 236 / +44
(0) 7971 221 972
About Psych Capital Plc
Psych Capital Plc identifies, funds and aims to support the
building of British and European companies across three core
pillars: therapeutic treatments, drug development, and data/AI. Its
mission is to support a new wave of innovators who are well
positioned to challenge the status-quo and revolutionise how
society deals with mental health conditions.
Through a network of analysts with deep industry knowledge and
capital markets expertise, Psych Capital is focussed on developing
a rigorously selected portfolio of industry leading companies at
the intersection of psychedelic medicine and technology.
The Psych Platform is a business-to-business media and content
platform for the psychedelic science and healthcare industry, and
it operates the website, https://psych.global/ . The Psych Platform
is a global B2B resource for networking, intelligence and insights,
servicing the industry through publications, newsletters and
engaging events. The Psych Platform has amassed a significant
global B2B audience, with over 20,000 subscribers to the
platform.
As a business-to-business media and content platform, the Psych
Platform also produces the PSYCH Symposium, a premium Live Event
series.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXBLGDLIXGDGDI
(END) Dow Jones Newswires
June 09, 2022 02:02 ET (06:02 GMT)
Shortwave Life Sciences (AQSE:PSY)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Shortwave Life Sciences (AQSE:PSY)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
